Characterizing mild cognitive impairment in incident Parkinson disease: The ICICLE-PD Study

OBJECTIVE:To describe the frequency of mild cognitive impairment (MCI) in Parkinson disease (PD) in a cohort of newly diagnosed incident PD cases and the associations with a panel of biomarkers. METHODS:Between June 2009 and December 2011, 219 subjects with PD and 99 age-matched controls participate...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neurology 2014-01, Vol.82 (4), p.308-316
Hauptverfasser: Yarnall, Alison J, Breen, David P, Duncan, Gordon W, Khoo, Tien K, Coleman, Shirley Y, Firbank, Michael J, Nombela, Cristina, Winder-Rhodes, Sophie, Evans, Jonathan R, Rowe, James B, Mollenhauer, Brit, Kruse, Niels, Hudson, Gavin, Chinnery, Patrick F, O’Brien, John T, Robbins, Trevor W, Wesnes, Keith, Brooks, David J, Barker, Roger A, Burn, David J
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 316
container_issue 4
container_start_page 308
container_title Neurology
container_volume 82
creator Yarnall, Alison J
Breen, David P
Duncan, Gordon W
Khoo, Tien K
Coleman, Shirley Y
Firbank, Michael J
Nombela, Cristina
Winder-Rhodes, Sophie
Evans, Jonathan R
Rowe, James B
Mollenhauer, Brit
Kruse, Niels
Hudson, Gavin
Chinnery, Patrick F
O’Brien, John T
Robbins, Trevor W
Wesnes, Keith
Brooks, David J
Barker, Roger A
Burn, David J
description OBJECTIVE:To describe the frequency of mild cognitive impairment (MCI) in Parkinson disease (PD) in a cohort of newly diagnosed incident PD cases and the associations with a panel of biomarkers. METHODS:Between June 2009 and December 2011, 219 subjects with PD and 99 age-matched controls participated in clinical and neuropsychological assessments as part of a longitudinal observational study. Consenting individuals underwent structural MRI, lumbar puncture, and genotyping for common variants of COMT, MAPT, SNCA, BuChE, EGF, and APOE. PD-MCI was defined with reference to the new Movement Disorder Society criteria. RESULTS:The frequency of PD-MCI was 42.5% using level 2 criteria at 1.5 SDs below normative values. Memory impairment was the most common domain affected, with 15.1% impaired at 1.5 SDs. Depression scores were significantly higher in those with PD-MCI than the cognitively normal PD group. A significant correlation was found between visual Pattern Recognition Memory and cerebrospinal β-amyloid 1–42 levels (β standardized coefficient = 0.350; p = 0.008) after controlling for age and education in a linear regression model, with lower β-amyloid 1–42 and 1–40 levels observed in those with PD-MCI. Voxel-based morphometry did not reveal any areas of significant gray matter loss in participants with PD-MCI compared with controls, and no specific genotype was associated with PD-MCI at the 1.5-SD threshold. CONCLUSIONS:In a large cohort of newly diagnosed PD participants, PD-MCI is common and significantly correlates with lower cerebrospinal β-amyloid 1–42 and 1–40 levels. Future longitudinal studies should enable us to determine those measures predictive of cognitive decline.
doi_str_mv 10.1212/WNL.0000000000000066
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3929202</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1492693303</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4707-26ee699b97dd655b2d77deb4559bbf3bce1483e0db11731cc28efa5e12f450cf3</originalsourceid><addsrcrecordid>eNqFkVtrFDEUgINY7Fr9ByLzIvgybS4zufgglLHqwlILVhR8CJnkzE7sXNZkpqX-erN221pfDIGEnO9cwofQC4IPCSX06Ovp6hA_WJw_QgtSUp5zRr89RguMqcyZFHIfPY3xB8YpKNQTtE8LxhlhYoG-V60Jxk4Q_C8_rLPedy6z43rwk7-EzPcb40MPw5T5IW3r3fZ-ZsKFH-I4ZM5HMBHeZOctZMtqWa1O8rN32edpdtfP0F5jugjPd-cB-vL-5Lz6mK8-fVhWx6vcFgKLnHIArlSthHO8LGvqhHBQF2Wp6rphtQVSSAbY1YQIRqylEhpTAqFNUWLbsAP09qbuZq57cDZNGEynN8H3Jlzr0Xj9MDL4Vq_HS80UVRTTVOD1rkAYf84QJ937aKHrzADjHDXhrMRMYqX-jxaKcsUYZgktblAbxhgDNHcTEay3CnVSqP9VmNJe_v2bu6RbZwl4tQNMtKZrgkla4j0niZAYy_v-V2OX_MaLbr6CoFsw3dT-6csJKXKKSYEJlTjfPgn2G-aOtCI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1492693303</pqid></control><display><type>article</type><title>Characterizing mild cognitive impairment in incident Parkinson disease: The ICICLE-PD Study</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><source>Journals@Ovid Complete</source><creator>Yarnall, Alison J ; Breen, David P ; Duncan, Gordon W ; Khoo, Tien K ; Coleman, Shirley Y ; Firbank, Michael J ; Nombela, Cristina ; Winder-Rhodes, Sophie ; Evans, Jonathan R ; Rowe, James B ; Mollenhauer, Brit ; Kruse, Niels ; Hudson, Gavin ; Chinnery, Patrick F ; O’Brien, John T ; Robbins, Trevor W ; Wesnes, Keith ; Brooks, David J ; Barker, Roger A ; Burn, David J</creator><creatorcontrib>Yarnall, Alison J ; Breen, David P ; Duncan, Gordon W ; Khoo, Tien K ; Coleman, Shirley Y ; Firbank, Michael J ; Nombela, Cristina ; Winder-Rhodes, Sophie ; Evans, Jonathan R ; Rowe, James B ; Mollenhauer, Brit ; Kruse, Niels ; Hudson, Gavin ; Chinnery, Patrick F ; O’Brien, John T ; Robbins, Trevor W ; Wesnes, Keith ; Brooks, David J ; Barker, Roger A ; Burn, David J ; ICICLE-PD Study Group</creatorcontrib><description>OBJECTIVE:To describe the frequency of mild cognitive impairment (MCI) in Parkinson disease (PD) in a cohort of newly diagnosed incident PD cases and the associations with a panel of biomarkers. METHODS:Between June 2009 and December 2011, 219 subjects with PD and 99 age-matched controls participated in clinical and neuropsychological assessments as part of a longitudinal observational study. Consenting individuals underwent structural MRI, lumbar puncture, and genotyping for common variants of COMT, MAPT, SNCA, BuChE, EGF, and APOE. PD-MCI was defined with reference to the new Movement Disorder Society criteria. RESULTS:The frequency of PD-MCI was 42.5% using level 2 criteria at 1.5 SDs below normative values. Memory impairment was the most common domain affected, with 15.1% impaired at 1.5 SDs. Depression scores were significantly higher in those with PD-MCI than the cognitively normal PD group. A significant correlation was found between visual Pattern Recognition Memory and cerebrospinal β-amyloid 1–42 levels (β standardized coefficient = 0.350; p = 0.008) after controlling for age and education in a linear regression model, with lower β-amyloid 1–42 and 1–40 levels observed in those with PD-MCI. Voxel-based morphometry did not reveal any areas of significant gray matter loss in participants with PD-MCI compared with controls, and no specific genotype was associated with PD-MCI at the 1.5-SD threshold. CONCLUSIONS:In a large cohort of newly diagnosed PD participants, PD-MCI is common and significantly correlates with lower cerebrospinal β-amyloid 1–42 and 1–40 levels. Future longitudinal studies should enable us to determine those measures predictive of cognitive decline.</description><identifier>ISSN: 0028-3878</identifier><identifier>EISSN: 1526-632X</identifier><identifier>DOI: 10.1212/WNL.0000000000000066</identifier><identifier>PMID: 24363137</identifier><identifier>CODEN: NEURAI</identifier><language>eng</language><publisher>Hagerstown, MD: American Academy of Neurology</publisher><subject>Aged ; Aged, 80 and over ; Amyloid beta-Peptides - cerebrospinal fluid ; Biological and medical sciences ; Case-Control Studies ; Cognitive Dysfunction - cerebrospinal fluid ; Cognitive Dysfunction - diagnosis ; Cognitive Dysfunction - etiology ; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases ; Female ; Geriatrics ; Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy ; Humans ; Intermediate Filament Proteins - cerebrospinal fluid ; Male ; Medical sciences ; Middle Aged ; Nervous system (semeiology, syndromes) ; Nervous system as a whole ; Neurology ; Neuropsychological Tests ; Parkinson Disease - epidemiology ; Peptide Fragments - cerebrospinal fluid ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Retrospective Studies ; Severity of Illness Index ; tau Proteins - cerebrospinal fluid</subject><ispartof>Neurology, 2014-01, Vol.82 (4), p.308-316</ispartof><rights>2014 American Academy of Neurology</rights><rights>2015 INIST-CNRS</rights><rights>2014 American Academy of Neurology 2014 American Academy of Neurology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4707-26ee699b97dd655b2d77deb4559bbf3bce1483e0db11731cc28efa5e12f450cf3</citedby><cites>FETCH-LOGICAL-c4707-26ee699b97dd655b2d77deb4559bbf3bce1483e0db11731cc28efa5e12f450cf3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=28178008$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24363137$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yarnall, Alison J</creatorcontrib><creatorcontrib>Breen, David P</creatorcontrib><creatorcontrib>Duncan, Gordon W</creatorcontrib><creatorcontrib>Khoo, Tien K</creatorcontrib><creatorcontrib>Coleman, Shirley Y</creatorcontrib><creatorcontrib>Firbank, Michael J</creatorcontrib><creatorcontrib>Nombela, Cristina</creatorcontrib><creatorcontrib>Winder-Rhodes, Sophie</creatorcontrib><creatorcontrib>Evans, Jonathan R</creatorcontrib><creatorcontrib>Rowe, James B</creatorcontrib><creatorcontrib>Mollenhauer, Brit</creatorcontrib><creatorcontrib>Kruse, Niels</creatorcontrib><creatorcontrib>Hudson, Gavin</creatorcontrib><creatorcontrib>Chinnery, Patrick F</creatorcontrib><creatorcontrib>O’Brien, John T</creatorcontrib><creatorcontrib>Robbins, Trevor W</creatorcontrib><creatorcontrib>Wesnes, Keith</creatorcontrib><creatorcontrib>Brooks, David J</creatorcontrib><creatorcontrib>Barker, Roger A</creatorcontrib><creatorcontrib>Burn, David J</creatorcontrib><creatorcontrib>ICICLE-PD Study Group</creatorcontrib><title>Characterizing mild cognitive impairment in incident Parkinson disease: The ICICLE-PD Study</title><title>Neurology</title><addtitle>Neurology</addtitle><description>OBJECTIVE:To describe the frequency of mild cognitive impairment (MCI) in Parkinson disease (PD) in a cohort of newly diagnosed incident PD cases and the associations with a panel of biomarkers. METHODS:Between June 2009 and December 2011, 219 subjects with PD and 99 age-matched controls participated in clinical and neuropsychological assessments as part of a longitudinal observational study. Consenting individuals underwent structural MRI, lumbar puncture, and genotyping for common variants of COMT, MAPT, SNCA, BuChE, EGF, and APOE. PD-MCI was defined with reference to the new Movement Disorder Society criteria. RESULTS:The frequency of PD-MCI was 42.5% using level 2 criteria at 1.5 SDs below normative values. Memory impairment was the most common domain affected, with 15.1% impaired at 1.5 SDs. Depression scores were significantly higher in those with PD-MCI than the cognitively normal PD group. A significant correlation was found between visual Pattern Recognition Memory and cerebrospinal β-amyloid 1–42 levels (β standardized coefficient = 0.350; p = 0.008) after controlling for age and education in a linear regression model, with lower β-amyloid 1–42 and 1–40 levels observed in those with PD-MCI. Voxel-based morphometry did not reveal any areas of significant gray matter loss in participants with PD-MCI compared with controls, and no specific genotype was associated with PD-MCI at the 1.5-SD threshold. CONCLUSIONS:In a large cohort of newly diagnosed PD participants, PD-MCI is common and significantly correlates with lower cerebrospinal β-amyloid 1–42 and 1–40 levels. Future longitudinal studies should enable us to determine those measures predictive of cognitive decline.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Amyloid beta-Peptides - cerebrospinal fluid</subject><subject>Biological and medical sciences</subject><subject>Case-Control Studies</subject><subject>Cognitive Dysfunction - cerebrospinal fluid</subject><subject>Cognitive Dysfunction - diagnosis</subject><subject>Cognitive Dysfunction - etiology</subject><subject>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</subject><subject>Female</subject><subject>Geriatrics</subject><subject>Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy</subject><subject>Humans</subject><subject>Intermediate Filament Proteins - cerebrospinal fluid</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nervous system (semeiology, syndromes)</subject><subject>Nervous system as a whole</subject><subject>Neurology</subject><subject>Neuropsychological Tests</subject><subject>Parkinson Disease - epidemiology</subject><subject>Peptide Fragments - cerebrospinal fluid</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Retrospective Studies</subject><subject>Severity of Illness Index</subject><subject>tau Proteins - cerebrospinal fluid</subject><issn>0028-3878</issn><issn>1526-632X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkVtrFDEUgINY7Fr9ByLzIvgybS4zufgglLHqwlILVhR8CJnkzE7sXNZkpqX-erN221pfDIGEnO9cwofQC4IPCSX06Ovp6hA_WJw_QgtSUp5zRr89RguMqcyZFHIfPY3xB8YpKNQTtE8LxhlhYoG-V60Jxk4Q_C8_rLPedy6z43rwk7-EzPcb40MPw5T5IW3r3fZ-ZsKFH-I4ZM5HMBHeZOctZMtqWa1O8rN32edpdtfP0F5jugjPd-cB-vL-5Lz6mK8-fVhWx6vcFgKLnHIArlSthHO8LGvqhHBQF2Wp6rphtQVSSAbY1YQIRqylEhpTAqFNUWLbsAP09qbuZq57cDZNGEynN8H3Jlzr0Xj9MDL4Vq_HS80UVRTTVOD1rkAYf84QJ937aKHrzADjHDXhrMRMYqX-jxaKcsUYZgktblAbxhgDNHcTEay3CnVSqP9VmNJe_v2bu6RbZwl4tQNMtKZrgkla4j0niZAYy_v-V2OX_MaLbr6CoFsw3dT-6csJKXKKSYEJlTjfPgn2G-aOtCI</recordid><startdate>20140128</startdate><enddate>20140128</enddate><creator>Yarnall, Alison J</creator><creator>Breen, David P</creator><creator>Duncan, Gordon W</creator><creator>Khoo, Tien K</creator><creator>Coleman, Shirley Y</creator><creator>Firbank, Michael J</creator><creator>Nombela, Cristina</creator><creator>Winder-Rhodes, Sophie</creator><creator>Evans, Jonathan R</creator><creator>Rowe, James B</creator><creator>Mollenhauer, Brit</creator><creator>Kruse, Niels</creator><creator>Hudson, Gavin</creator><creator>Chinnery, Patrick F</creator><creator>O’Brien, John T</creator><creator>Robbins, Trevor W</creator><creator>Wesnes, Keith</creator><creator>Brooks, David J</creator><creator>Barker, Roger A</creator><creator>Burn, David J</creator><general>American Academy of Neurology</general><general>Lippincott Williams &amp; Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7TK</scope><scope>5PM</scope></search><sort><creationdate>20140128</creationdate><title>Characterizing mild cognitive impairment in incident Parkinson disease: The ICICLE-PD Study</title><author>Yarnall, Alison J ; Breen, David P ; Duncan, Gordon W ; Khoo, Tien K ; Coleman, Shirley Y ; Firbank, Michael J ; Nombela, Cristina ; Winder-Rhodes, Sophie ; Evans, Jonathan R ; Rowe, James B ; Mollenhauer, Brit ; Kruse, Niels ; Hudson, Gavin ; Chinnery, Patrick F ; O’Brien, John T ; Robbins, Trevor W ; Wesnes, Keith ; Brooks, David J ; Barker, Roger A ; Burn, David J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4707-26ee699b97dd655b2d77deb4559bbf3bce1483e0db11731cc28efa5e12f450cf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Amyloid beta-Peptides - cerebrospinal fluid</topic><topic>Biological and medical sciences</topic><topic>Case-Control Studies</topic><topic>Cognitive Dysfunction - cerebrospinal fluid</topic><topic>Cognitive Dysfunction - diagnosis</topic><topic>Cognitive Dysfunction - etiology</topic><topic>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</topic><topic>Female</topic><topic>Geriatrics</topic><topic>Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy</topic><topic>Humans</topic><topic>Intermediate Filament Proteins - cerebrospinal fluid</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nervous system (semeiology, syndromes)</topic><topic>Nervous system as a whole</topic><topic>Neurology</topic><topic>Neuropsychological Tests</topic><topic>Parkinson Disease - epidemiology</topic><topic>Peptide Fragments - cerebrospinal fluid</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Retrospective Studies</topic><topic>Severity of Illness Index</topic><topic>tau Proteins - cerebrospinal fluid</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yarnall, Alison J</creatorcontrib><creatorcontrib>Breen, David P</creatorcontrib><creatorcontrib>Duncan, Gordon W</creatorcontrib><creatorcontrib>Khoo, Tien K</creatorcontrib><creatorcontrib>Coleman, Shirley Y</creatorcontrib><creatorcontrib>Firbank, Michael J</creatorcontrib><creatorcontrib>Nombela, Cristina</creatorcontrib><creatorcontrib>Winder-Rhodes, Sophie</creatorcontrib><creatorcontrib>Evans, Jonathan R</creatorcontrib><creatorcontrib>Rowe, James B</creatorcontrib><creatorcontrib>Mollenhauer, Brit</creatorcontrib><creatorcontrib>Kruse, Niels</creatorcontrib><creatorcontrib>Hudson, Gavin</creatorcontrib><creatorcontrib>Chinnery, Patrick F</creatorcontrib><creatorcontrib>O’Brien, John T</creatorcontrib><creatorcontrib>Robbins, Trevor W</creatorcontrib><creatorcontrib>Wesnes, Keith</creatorcontrib><creatorcontrib>Brooks, David J</creatorcontrib><creatorcontrib>Barker, Roger A</creatorcontrib><creatorcontrib>Burn, David J</creatorcontrib><creatorcontrib>ICICLE-PD Study Group</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Neurosciences Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yarnall, Alison J</au><au>Breen, David P</au><au>Duncan, Gordon W</au><au>Khoo, Tien K</au><au>Coleman, Shirley Y</au><au>Firbank, Michael J</au><au>Nombela, Cristina</au><au>Winder-Rhodes, Sophie</au><au>Evans, Jonathan R</au><au>Rowe, James B</au><au>Mollenhauer, Brit</au><au>Kruse, Niels</au><au>Hudson, Gavin</au><au>Chinnery, Patrick F</au><au>O’Brien, John T</au><au>Robbins, Trevor W</au><au>Wesnes, Keith</au><au>Brooks, David J</au><au>Barker, Roger A</au><au>Burn, David J</au><aucorp>ICICLE-PD Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Characterizing mild cognitive impairment in incident Parkinson disease: The ICICLE-PD Study</atitle><jtitle>Neurology</jtitle><addtitle>Neurology</addtitle><date>2014-01-28</date><risdate>2014</risdate><volume>82</volume><issue>4</issue><spage>308</spage><epage>316</epage><pages>308-316</pages><issn>0028-3878</issn><eissn>1526-632X</eissn><coden>NEURAI</coden><abstract>OBJECTIVE:To describe the frequency of mild cognitive impairment (MCI) in Parkinson disease (PD) in a cohort of newly diagnosed incident PD cases and the associations with a panel of biomarkers. METHODS:Between June 2009 and December 2011, 219 subjects with PD and 99 age-matched controls participated in clinical and neuropsychological assessments as part of a longitudinal observational study. Consenting individuals underwent structural MRI, lumbar puncture, and genotyping for common variants of COMT, MAPT, SNCA, BuChE, EGF, and APOE. PD-MCI was defined with reference to the new Movement Disorder Society criteria. RESULTS:The frequency of PD-MCI was 42.5% using level 2 criteria at 1.5 SDs below normative values. Memory impairment was the most common domain affected, with 15.1% impaired at 1.5 SDs. Depression scores were significantly higher in those with PD-MCI than the cognitively normal PD group. A significant correlation was found between visual Pattern Recognition Memory and cerebrospinal β-amyloid 1–42 levels (β standardized coefficient = 0.350; p = 0.008) after controlling for age and education in a linear regression model, with lower β-amyloid 1–42 and 1–40 levels observed in those with PD-MCI. Voxel-based morphometry did not reveal any areas of significant gray matter loss in participants with PD-MCI compared with controls, and no specific genotype was associated with PD-MCI at the 1.5-SD threshold. CONCLUSIONS:In a large cohort of newly diagnosed PD participants, PD-MCI is common and significantly correlates with lower cerebrospinal β-amyloid 1–42 and 1–40 levels. Future longitudinal studies should enable us to determine those measures predictive of cognitive decline.</abstract><cop>Hagerstown, MD</cop><pub>American Academy of Neurology</pub><pmid>24363137</pmid><doi>10.1212/WNL.0000000000000066</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0028-3878
ispartof Neurology, 2014-01, Vol.82 (4), p.308-316
issn 0028-3878
1526-632X
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3929202
source MEDLINE; Alma/SFX Local Collection; Journals@Ovid Complete
subjects Aged
Aged, 80 and over
Amyloid beta-Peptides - cerebrospinal fluid
Biological and medical sciences
Case-Control Studies
Cognitive Dysfunction - cerebrospinal fluid
Cognitive Dysfunction - diagnosis
Cognitive Dysfunction - etiology
Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
Female
Geriatrics
Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy
Humans
Intermediate Filament Proteins - cerebrospinal fluid
Male
Medical sciences
Middle Aged
Nervous system (semeiology, syndromes)
Nervous system as a whole
Neurology
Neuropsychological Tests
Parkinson Disease - epidemiology
Peptide Fragments - cerebrospinal fluid
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Retrospective Studies
Severity of Illness Index
tau Proteins - cerebrospinal fluid
title Characterizing mild cognitive impairment in incident Parkinson disease: The ICICLE-PD Study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T02%3A51%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Characterizing%20mild%20cognitive%20impairment%20in%20incident%20Parkinson%20disease:%20The%20ICICLE-PD%20Study&rft.jtitle=Neurology&rft.au=Yarnall,%20Alison%20J&rft.aucorp=ICICLE-PD%20Study%20Group&rft.date=2014-01-28&rft.volume=82&rft.issue=4&rft.spage=308&rft.epage=316&rft.pages=308-316&rft.issn=0028-3878&rft.eissn=1526-632X&rft.coden=NEURAI&rft_id=info:doi/10.1212/WNL.0000000000000066&rft_dat=%3Cproquest_pubme%3E1492693303%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1492693303&rft_id=info:pmid/24363137&rfr_iscdi=true